Pharmacy in Zelzate · BE. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for Deraphar combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Deraphar, a pharmacy, is registered at an address in Zelzate, Belgium. The company was founded in 1989, incorporated as a Besloten Vennootschap.
Deraphar is listed in Belgian Crossroads Bank for Enterprises (KBO) under registry number 0439109003 and VAT number BE0439109003. This profile consolidates KBO registry, NBB/CBSO annual accounts into one indexable company dossier.
Within the Belgian NACE 47730 cluster, public-record data is filed annually via the national company registry.
For fiscal year 2024, the gross-margin line stands at €191,616. EBITDA comes in at €64,651. Because this line is gross margin from an abbreviated filing, not reported turnover, it is treated as public context rather than an automatic valuation base.
An indicative valuation band is available for Deraphar, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2024.
The data on this page is a public, point-in-time projection of Deraphar's regulator-filed footprint, built to support indicative valuation bands, sellability context, and acquisition research.
Public regulator-filed figures across one year.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 2024 | €191,616 | €64,651 | €855,507 | €358,308 | - |
Deraphar was founded in 1989 and is registered with Belgian Crossroads Bank for Enterprises (KBO), incorporated as a Besloten Vennootschap.
Deraphar is registered under NACE 47730: NACE 47730. That places the business within the Belgian cluster for this activity.
According to the company registry, Deraphar is based in Zelzate, BE.
The most recently filed annual accounts cover fiscal year 2024, publicly available via Belgian Crossroads Bank for Enterprises (KBO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for Deraphar may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Public profiles for peers in the same industry and country. Click through to compare filings and indicative valuations.
